Skip to main content Skip to secondary navigation
Main content start

Katja Hofmann

As drug prices in the U.S. are rising, many patients must decide whether to compromise their financial or medical health when filling a prescription. My research studies policy and market-driven interventions that aim to lower the financial burden of prescription drugs. Studying the role of the government, insurance companies, and providers, my goal is to understand how financial incentives shape patients’ health outcomes, as well as how to improve the design of health insurance. Empirical methods from economics build the framework of my analyses, while new insights from the medical literature improve the measurement of outcomes of interest.